trending Market Intelligence /marketintelligence/en/news-insights/trending/dzh5p3fCUQ-yjRLbG5i7ow2 content esgSubNav
In This List

Allergan to acquire Repros Therapeutics

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Allergan to acquire Repros Therapeutics

Allergan plc is acquiring Repros Therapeutics Inc. for 67 U.S. cents per share in cash.

The deal is backed by the Repros Therapeutics board and is expected to close during the first quarter of 2018.

Repros Therapeutics focuses on developing small molecule drugs that treat male and female reproductive disorders.

Stifel Nicolaus & Co. Inc. is serving as the exclusive financial adviser to Repros in the deal, with Morgan Lewis & Bockius LLP acting as legal counsel.

Covington & Burling LLP is acting as Allergan's legal counsel.